HOSPITAL UNIVERSITARIO RUBER

Departamento

Foto de HOSPITAL UNIVERSITARIO RUBER

Foto de National Taiwan University Hospital

National Taiwan University Hospital

Taipéi, Taiwán

Publicaciones en colaboración con investigadores/as de National Taiwan University Hospital (4)

2024

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
Journal of Clinical Oncology, Vol. 42, Núm. 9, pp. 987-993

2023

Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
JAMA network open, Vol. 6, Núm. 11, pp. e2342107

2022

GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813

2016

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366